Related Experiment Videos
Peripheral acute leukemia: high peripheral but low-marrow blast count
J D Cason1, J M Trujillo, E H Estey
1Department of Laboratory Medicine, University of Texas M.D. Anderson Cancer Center, Houston.
Abstract:
We report five patients who had greater than 30% peripheral blasts and less than 30% marrow blasts. By the current standards these cases would be classified as myelodysplastic syndrome. Four of five patients progressed to acute leukemia within approximately 1 1/2 months of developing greater than 30% peripheral blasts. Two of these four patients had evidence of acute leukemia by criteria other than marrow involvement at the time of presentation: one patient had evidence of multifocal dermal involvement; and the other patient had a cytogenetic abnormality, t(8;21), found predominantly in acute leukemia. The fifth patient developed acute leukemia 2 years after initial presentation with greater than 30% peripheral blasts. Although our series of patients is small, it does suggest that patients who have greater than 30% peripheral blasts should be considered an acute leukemia, even with less than 30% marrow blasts.
Insights
Patients with over 30% peripheral blasts, even with less than 30% marrow blasts, may have acute leukemia. This finding suggests a reclassification for these myelodysplastic syndrome cases to improve early diagnosis and treatment.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Current diagnostic criteria for acute myeloid leukemia (AML) rely heavily on marrow blast percentage.
Observation:
- Five patients presented with >30% peripheral blasts and <30% marrow blasts.
- These cases would typically be classified as MDS under existing standards.
- Four patients progressed to AML within 1.5 months; one progressed 2 years later.
Findings:
- Peripheral blast percentage may be a critical indicator for AML diagnosis.
- Two patients showed AML evidence beyond marrow blasts: dermal involvement and t(8;21) cytogenetic abnormality.
- The study suggests reclassifying patients with >30% peripheral blasts as AML, irrespective of marrow blast count.
Implications:
- This challenges current AML diagnostic thresholds, potentially leading to earlier intervention.
- Consideration of peripheral blast count alongside marrow blasts could refine AML classification.
- Earlier AML diagnosis may improve patient outcomes and treatment strategies.